Coelho, T., Dispenzieri, A., Grogan, M., Conceição, I., Waddington-Cruz, M., Kristen, A. V., … THAOS investigators. (2023). Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay. Amyloid, 30(4), 445–448. https://doi.org/10.1080/13506129.2023.2229484

Coelho, Teresa, Angela Dispenzieri, Martha Grogan, Isabel Conceição, Márcia Waddington-Cruz, Arnt V. Kristen, Jonas Wixner, et al. “Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay.” Amyloid 30, no. 4 (December 2023): 445–48. https://doi.org/10.1080/13506129.2023.2229484.

Coelho T, Dispenzieri A, Grogan M, Conceição I, Waddington-Cruz M, Kristen AV, et al. Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay. Amyloid. 2023 Dec;30(4):445–8.

Coelho, Teresa, et al. “Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay.” Amyloid, vol. 30, no. 4, Dec. 2023, pp. 445–48. Pubmed, doi:10.1080/13506129.2023.2229484.

Coelho T, Dispenzieri A, Grogan M, Conceição I, Waddington-Cruz M, Kristen AV, Wixner J, Diemberger I, Gonzalez-Moreno J, Maurer MS, Planté-Bordeneuve V, Garcia-Pavia P, Tournev I, Gonzalez-Costello J, Cariou E, González-Duarte A, Glass O, Chapman D, Amass L, THAOS investigators. Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay. Amyloid. 2023 Dec;30(4):445–448.